Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving erlotinib together with celecoxib works in
treating patients with recurrent stage IIIB or stage IV non-small cell lung cancer. Erlotinib
and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor
cell growth. Celecoxib may slow the growth of a tumor by stopping blood flow to the tumor.
Combining erlotinib with celecoxib may kill more tumor cells.
.